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Loss of functional pRB is not a ubiquitous feature of
B-cell malignancies
AJ Sinclair and V Frost
School of Biological Sciences, University of Sussex, Brighton, E Sussex BN1 9QG, UK
Summary Human cancers frequently sustain genetic mutations that alter the function of their G1 cell cycle control check point. These include
changes to the retinoblastoma gene and to the genes that regulate its phosphorylation, such as the cyclin-dependent kinase inhibitor p16INK4a.
Altered expression of retinoblastoma protein (pRb) is associated with non-Hodgkin’s lymphoma, particularly centroblastic and Burkitt’s
lymphomas. pRb is expressed in normal B-cells and its regulatory phosphorylation pathway is activated in response to a variety of stimuli.
Since human B-lymphoma-derived cell lines are often used as in vitro model systems to analyse the downstream effects of signal
transduction, we examined the functional status of pRb in a panel of human B-cell lines. We identified eleven cell lines which express the
hyperphosphorylated forms of pRb. Furthermore, we suggest that the pRb protein appears to be functional in these cell lines.
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Article no. bjoc.1998.0408Many human cancers harbour genetic changes that alter the func-
tion of the G1 cell cycle control check point (reviewed in Sherr
and Roberts, 1995; Bartek et al, 1996; Hall and Peters, 1996;
Palmero and Peters, 1996; Herwig and Strauss, 1997). The
common outcome of these changes is the functional deregulation
of the retinoblastoma protein (pRb). pRb directly interacts with
and regulates the activity of a series of RNA polymerase I, II and
III dependent transcription factors including members of the E2F
family, MyoD and Elf-1 (Bartek et al, 1996; Sanchez and
Dynlacht, 1996; Herwig and Strauss, 1997). The activity of pRb is
regulated in turn by its phosphorylation status (Weinberg, 1995;
Bartek et al, 1996; Herwig and Strauss, 1997; Mittnacht, 1998). In
non-proliferating or quiescent cells, pRb is hypophosphorylated
and active. However, in response to appropriate growth condi-
tions, cells enter into the G1 phase of the cell division cycle, and
cyclin-dependent kinase 4 (cdk4) and cdk6, in conjunction with
members of the cyclin D family, and cdk2, in conjunction with
cyclin E, phosphorylate pRb protein resulting in its inactivation.
This releases both the pRb-associated transcription factors and the
cell cycle control check point and allows cells to progress from G1
into S phase (Weinberg, 1995; Bartek et al, 1996; Herwig and
Strauss, 1997; Mittnacht, 1998). Members of the p16INK4a and
p21CIP1 cdk-inhibitor families also influence the activity of pRb by
directly inhibiting phosphorylation of pRb protein by the cdks
(Bartek et al, 1996; Herwig and Strauss, 1997; Mittnacht, 1998).
Thus, information from both positive and negative extracellular
signals is integrated into a simple ‘stop’ or ‘go’ message at the G1
checkpoint by influencing the ability of the cyclin D–cdk and
cyclin E–cdk complexes to phosphorylate pRb protein.
The retinoblastoma gene itself is a target for genetic alterations
in many types of cancer (reviewed in Palmero and Peters, 1996).
The resulting deletions and point mutations either destroy the670
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Correspondence to: AJ Sinclaircoding capacity or else encode for non-functional versions of pRb
protein (Cowell and Hogg, 1992; Weinberg, 1992). In cells that
have sustained homozygous mutations to the retinoblastoma gene,
pRb is constitutively inactive and, as a consequence, the pRb-
dependent cell cycle check point cannot be imposed. Thus, muta-
tion of the retinoblastoma gene can contribute to the deregulated
proliferation of cancer cells.
The retinoblastoma gene is expressed in a cell cycle-dependent
manner in normal human B-cells. As quiescent (Go) cells enter
into the cell division cycle in response to relevant extracellular
signals, two changes to pRb protein become apparent: the overall
level of expression increases and the protein becomes phosphoryl-
ated on multiple sites (Sinclair et al, 1994, 1998; Hollyoake et al,
1995; Kempkes et al, 1995; Szekely et al, 1995; Cannell et al
1996). Altered expression of pRb has been described in primary
samples derived from high grade non-Hodgkin’s lymphoma
(NHL) (Martinez et al, 1993) and expression is lost in 58% of
centroblastic and Burkitt’s lymphomas (Weide et al, 1994).
Cell lines derived from Burkitt’s lymphomas and from
Epstein–Barr virus (EBV) transformed human B-cells are
frequently used as in vitro model systems to ask questions about
the effects of extracellular signalling on the proliferation of B-cells
(for example, Sinclair et al, 1993; Holder et al, 1993; Allday et al,
1995; Arvanitakis et al, 1995; MacDonald et al, 1996). Since pRb
is involved in integrating a wide range of signal transduction path-
ways, it is important to determine whether or not established
human B-cell lines express functional pRb protein.
In this report, the expression and the functional status of the
retinoblastoma gene in 11 human B-cell lines are examined.
MATERIALS AND METHODS
Cell culture
The human B-lymphoid cell lines were maintained in RPMI
supplemented with 15% (v/v) fetal calf serum, penicillin and strep-
tomycin at between 2 and 8 · 105 cells per ml to ensure that they
were in exponential growth. Ramos (Klein et al, 1975), DG75
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Figure 1 Expression of pRb in B-lymphoid cells. Total protein extracts from
a series of B-lymphoid cell lines and control cell lines were fractionated on a
10% SDS-acrylamide gel. The location of the molecular weight standards is
indicated on the left (in kDa). The expression of pRb protein was determined
by Western blot analysis. The migration of the hypophosphorylated and
hyperphosphorylated forms of pRb are shown on the right(Ben-Bassat et al, 1977), Akata (Takada, 1984), Rael (Klein et al,
1972), Mutu Cl 179 (Gregory et al, 1990), Mutu Cl 148 (Gregory
et al, 1990) and Jijoye (Hinuma et al, 1967) were originally
derived from Burkitt’s lymphomas. LCL#3 (Sinclair et al, 1994),
B95-8PF (Farrell et al, 1991) and IB4 (King et al, 1980) were
established by immortalization of primary B-cells with the B95-8
strain of EBV. BJAB was originally derived from an EBV-negative
B-lymphoma and does not harbour any of the c-myc/immuno-
globulin translocations that are characteristic of Burkitt’s
lymphoma (Clements et al, 1975; Menezes et al, 1975). SAOS
(Diller et al, 1990) and U2OS (Ponten and Saksela, 1967) were
originally derived from osteosarcomas.
Quiescent primary B-cells were isolated from donated human
blood using affinity purification with anti-CD19 coated magnetic
beads (Dynal) as described previously (Sinclair et al, 1994;
Sinclair and Farrell, 1995).
Protein analysis
Total protein extracts were prepared from exponentially growing
cell lines and from quiescent primary B-cells as described
previously (Cannell et al, 1996). The protein concentrations were
normalized after comparing the absorption at 280 nm. A total of
100 m g of each extract was fractionated on a sodium dodecyl
sulphate (SDS)-polyacrylamide gel, transferred to polyvinylidene
difluoride (PVDF) membrane (Immobilon-P) and processed as
described previously (Cannell et al, 1996).
For the analysis of pRb protein, extracts were fractionated in a
10% gel and a monoclonal antibody used to detect the protein
(14001A; Pharmingen). For the analysis of p16INK4a protein,
extracts were fractionated in a 15% gel and a monoclonal antibody
was used to detect the protein (DCS50; Lukas et al, 1995a). For
the analysis of p15INK4b protein, extracts were fractionated in a
15% gel and a rabbit polyclonal antisera was used to detect the
protein (K-18; Santa Cruz). For cdk4, proteins were fractionated in
a 12.5% gel and a rabbit polyclonal antiserum was used to detect
the protein (Bates et al, 1994). In each case an HRP-conjugated
species-specific secondary antibody step was included and the
signals were detected by enhanced chemiluminescence (ECL)
after exposure to autoradiography (Amersham).
Complex formation
Extracts were prepared by lysing cells in NP40 lysis buffer (50 mM
Hepes pH 8.0; 1% (v/v) NP-40; 0.1% (v/v) Tween-20; 150 mM
sodium chloride; 1 mM EDTA; 2.5 mM EGTA; 1 mM NaF; 10%
(v/v) glycerol, 1 mM dithiothreitol; ‘complete protease inhibitor’
(Boehringer Mannheim)). Debris was removed from the extract by
centrifugation (1000 rpm for 10 min in a Beckman J6B centrifuge).
The extract was precleared by incubation with a mixture of protein
A and protein G Sepharose for 45 min rocking at 4° C. Sepharose
beads were removed by centrifugation (1000 rpm for 10 min in a
Beckman J6B centrifuge). Cyclin D3 and any associated proteins
were isolated from the precleared extract by precipitation with a
cyclin D3 monoclonal antibody (DCS28; Welcker et al, 1996;
Bartokova et al, 1998). For the IB4 extract only, a combination of
DCS28 and a cyclin D2-specific antibody, DCS5.2 (Lukas et al,
1995b) was used to isolate both cyclin D2 and cyclin D3 associated
proteins. A mock precipitation with control mouse antibodies
(Sigma) was undertaken in parallel. The precipitated complexes
were collected on a combination of Protein A and Protein G© Cancer Research Campaign 1999Sepharose beads (Sigma) and washed extensively with lysis buffer
and then once with 50 mM Tris–HCl, pH 7.5. The proteins were
then eluted from the beads by heating at 95° C for 5 min in 2 3 PS
buffer (0.12 M Tris pH 6.8; 4% (v/v) SDS; 20% (w/v) glycerol; 2%
(v/v) b -mercaptoethanol; 0.01% (w/v) bromophenol blue) and
fractionated on a 12.5% SDS-polycrylamide gel. Cdk4 protein in
the complexes was detected by Western blot analysis using the
rabbit polyclonal antiserum described above (Bates et al, 1994).
Densitometric analysis
The relative level of p16INK4a protein detected by Western blot
analysis was quantitated by densitometric analysis using Image
Quant (Pharmacia) software.
RESULTS
pRb protein is expressed and regulated by
phosphorylation in human B-lymphoid cell lines
The expression of pRb protein was surveyed in a series of well-
characterized cell lines originally derived from Burkitt’s
lymphomas; Ramos, DG75, Akata, Rael, Mutu Cl 179, Mutu Cl
148 and Jijoye (Figure 1), and a B-cell lymphoma, BJAB (data not
shown). In addition, three lymphoblastoid cell lines that had been
previously immortalized with EBV in vitro; LCL#3 and B95-8PF
(Figure 1) and IB4 (data not shown), were included in the analysis.
The osteosarcoma cell lines, SAOS and U2OS, were analysed in
parallel as controls. The SAOS cell line is known not to express
detectable pRb protein, whereas the U2OS cell line expresses
similar levels of pRb protein as proliferating primary human cells
(Koh et al, 1995; Lukas et al, 1995a) (Figure 1). A single band of
low intensity was observed in the sample of normal primary B-cells
(PB). These cells were isolated from the peripheral circulation and
the majority of the population were quiescent naive B-cells
(Sinclair et al, 1994; Sinclair and Farrell, 1995). The single pRb
band corresponded to the hypophosphorylated form of pRb which
is characteristic of this cell type (Cannell et al, 1996). In contrast,
all of the B-cell lines and the U2OS cell line displayed stronger
signals with the pRb antibody. These appeared as a broad ladder or
smear of bands, which corresponded to the multiply phosphory-
lated forms of pRb that are characteristic of proliferating cells
(Buchkovich et al, 1989; Ludlow et al, 1989; Xu et al, 1989).British Journal of Cancer (1999) 80(5/6), 670–675
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Thus, all 11 of the B-lymphoid cell lines contained equivalent
levels of pRb protein, which is present in the hyperphosphorylated
forms expected for proliferating cells.
Figure 2 Loss of functional pRb leads to increased p16INK4a expression.
(A) The feedback loop linking pRb with the expression of p16INK4a is shown.
(B) When pRb function is lost or compromised, the feedback loop is broken
and p16INK4a expression is elevated
Figure 3 Expression of p16INK4a and p15INK4b in B-lymphoid cells. (A, B)
Total protein extracts from a series of B-lymphoid cell lines and control cell
lines, as in Figure 1, were fractionated in duplicate on 15% SDS-acrylamide
gels. The location of the molecular weight standards is indicated on the left
(in kDa). The expression of p16INK4a protein (A) and p15INK4b protein (B) were
determined by Western blot analysis. The migration of p16INK4a and p15INK4b
are shown on the right. (C) The signals from p16INK4a protein were quantitated
by densitometric analysis using Image Quant (Pharmacia) software. The
levels of expression are plotted in arbitrary units with the level in SAOS cells
set at 100
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Although non-functional mutant forms of pRb do not generally
exist in hyperphosphorylated forms (Scheffner et al, 1991;
Templeton et al, 1991), the analysis of protein expression by
Western blotting was not able to distinguish unequivocally
between functional proteins and those that had sustained either
small deletions within the coding sequence or point mutations
which rendered them non-functional. We therefore sought further
evidence to define whether the pRb proteins observed in this panel
of B-cell lines were functional.
One consequence of the loss of pRb function in human cell lines
is the increased expression of the cdkI gene p16INK4a (Serrano et al,
1993; Li et al, 1994; Otterson et al, 1994; Tam et al, 1994; Aagaard
et al, 1995; He et al, 1995; Kelley et al, 1995; Kratzke et al, 1995;
Lukas et al, 1995a; Musgrove et al, 1995; Parry et al, 1995;
Shapiro et al, 1995a,b; Bartkova et al, 1996; Hara et al, 1996;
Khleif et al, 1996; Itoh et al, 1997; Ruas and Peters, 1998). As
illustrated in Figure 2, p16INK4a was expressed at basal levels in
cells containing functional pRb. This was achieved by the repres-
sion of p16INK4a transcription by pRb protein. This repression
formed part of a homeostatic feedback loop in which hypophos-
phorylated, active pRb repressed the transcription of p16INK4a,
maintaining basal levels of p16INK4a protein in the cell and allowing
cdk4 and cdk6 to form active complexes with cyclin D and so
phosphorylate pRb. As illustrated in Figure 2B, it is apparent that
the functional inactivation of pRb disrupted this regulation,
resulting in increased transcription of p16INK4a and the accumula-
tion of high levels of p16INK4a protein within a cell. Indeed, it has
been observed that human cell lines lacking functional pRb
contain so much p16INK4a protein that no cyclin D–cdk4 or cyclin
D–cdk6 complexes are formed (for example Serrano et al, 1993;
Tam et al, 1994; Aagaard et al, 1995; Parry et al, 1995).
Thus, in a situation where apparently full-length pRb is
expressed and the p16INK4a locus has not been deleted or silenced
by methylation, the functional status of pRb can be questionedBritish Journal of Cancer (1999) 80(5/6), 670–675experimentally (i) by quantitating the relative level of p16INK4a
protein within cells and (ii) by asking whether cyclin D–cdk4
and/or cyclin D–cdk6 complexes are present within the cell line.
In order to question whether pRb is functional in the panel of B-
cell lines, the level of expression of p16INK4a protein was compared
between the B-cell lines and the control cell lines. All of the
samples were fractionated on the same gel and analysed in an iden-
tical fashion. As had been shown previously, the U2OS cell line
did not express p16INK4a protein whereas the SAOS cell line, which
did not express any pRb protein (Figure 1), contained characteris-
tically high levels of p16INK4a protein (Lukas et al, 1995a) (Figure
3A). These two lines were included in the analysis as positive and
negative controls. In comparison to the signal observed in SAOS
cells, the normal B-cells (PB) and the B-lymphoid cell lines
expressed p16INK4a protein at levels that were just detectable in this
assay (Figure 3A). The expression of the related cdkI p15INK4a,
which is not regulated by pRb, was also compared between this
panel of cell lines. p15INK4b did not show the same marked varia-
tion in expression (Figure 3B).
When the level of p16INK4a protein in the cell lines was quanti-
tated, it became clear that there was some variation in the levels of© Cancer Research Campaign 1999
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Cell Line DG75 Rael Ramos IB4
IP antibody – C D3 – C D3 – C D3 – C D2
–CDK4
Figure 4 Formation of cyclin D–cdk4 complexes in DG75 cells. NP-40
extracts were prepared from the indicated cell lines. After incubation with
either anti-cyclin D3 alone (D3) or a combination of anti-cyclin D3 and anti-
cyclin D2 primary antibodies (D2), or a control mouse IgG (C), or no antibody
(–) the resulting complexes were isolated on a combination of protein A and
protein G Sepharose beads and fractionated on a 12.5% SDS-acrylamide
gel. The presence of cdk4 protein in the complexes was determined by
Western blot analysisp16INK4a protein between the B-cell lines (Figure 3C). However,
the striking feature of the analysis was that none of the B-
lymphoid cell lines expressed p16INK4a proteins at significantly
higher levels than the normal primary B-cells, and none at levels
comparable to that observed in the SAOS cell line. Thus, the level
of p16INK4a protein within these B-lymphoid cell lines was consis-
tent with the retention of functional pRb.
As a further test of the functional status of pRb within these
cells, we analysed whether cyclin D–cdk4 complexes could be
formed in four representative cell lines: an LCL (IB4), an EBV-
positive Burkitt’s lymphoma (Rael) and two EBV-negative
Burkitt’s lymphoma cell lines (DG75 and Ramos). These cell lines
displayed characteristic differences in their expression of members
of the cyclin D family; LCLs expressed predominantly cyclin D2,
whereas the other cell lines expressed only cyclin D3 (Palmero et
al, 1993; Pokrovskaja et al, 1996; Bartekova et al, 1998). In all
four cell lines, isolation of complexes containing the relevant
cyclin D protein resulted in the co-purification of cdk4 (Figure 4).
Thus, the p16INK4a protein in these cell lines remained below the
threshold required to disrupt cyclin D–cdk4 complexes, which
further strengthened our general conclusion that pRb is functional
in this panel of human B-lymphoid-derived cell lines.
DISCUSSION
Although the incidence of genetic alteration to the retinoblastoma
gene is high in non-Hodgkin’s lymphomas (NHL) (Martinez et al,
1993; Weide et al, 1994), we have identified 11 human B-cell lines
which express pRb protein. This suggests that at least one allele of
the retinoblastoma gene is intact in the cell lines. Furthermore,
since (i) the pRb/p16INK4a feedback loop does not appear to have
been disrupted and (ii) cyclin D–cdk4 complexes exist in the cells,
this suggests that the pRb protein is functional and so inactivating
point mutations are unlikely to have occurred. These cell lines may
therefore prove to be a useful background in which to investigate
the consequences of experimentally disrupting pRb function in
human B-cells.
It is intriguing that the published incidence of pRb lesions is
higher in B-lymphoid malignancies than B-lymphoid cell lines.
However, the discovery that the loss of functional pRb can
promote apoptosis (Morganbesser et al, 1994; Pan and Griep,
1994) may suggest an explanation for this difference. Thus, a
model can be formulated whereby B-cell tumours lacking func-
tional pRb exist in vivo due to the presence of survival factors© Cancer Research Campaign 1999expressed by neighbouring cells; however, once they are removed
from their microenvironment and placed into in vitro culture, they
will not survive. Thus, it is likely that established B-lymphoid cell
lines represent only a subset of the tumours.
The presence of slower migrating bands of pRb, as seen in
Figure 1, shows that the pRb phosphorylation pathway is active in
these cells. However, since components of this pathway are
frequently subject to mutation in lymphoid malignancies it is
worth considering whether other components of the pathway are
likely to be compromised in these cell lines.
i. A chromosomal translocation, t(11;14) (Banks et al, 1992;
Shivdasani et al, 1993; Harris et al, 1994), which juxtaposes
the cyclin D1 gene with an immunoglobulin enhancer and thus
drives the unscheduled expression of cyclin D1 in B-cells
(reviewed in Hall and Peters, 1996), is associated with a subset
of B-lymphomas (Mantle cell lymphomas). However, this
translocation has not been found in Burkitt’s lymphomas,
which is consistent with the fact that no cyclin D1 protein or
mRNA has been detected in an extensive group of cell lines
derived from Burkitt’s lymphomas or EBV immortalized B-
cells (Palmero et al, 1993; Pokrovskaja et al, 1996).
ii. Homozygous deletion of the MTS1 (CDKN2A, p16INK4a) locus
is detected in a wide range of lymphoid malignancies
(reviewed in Ruas and Peters, 1998). This results in a lack of
expression of p16INK4a protein. As shown in Figure 3A, we
were able to detect p16INK4a protein of the expected molecular
weight in all of the B-cell lines, which implies that the locus
has not been lost from this panel of cell lines.
iii. Point mutations within the p16INK4a coding sequence have also
been observed in non-lymphoid malignancies (reviewed in
Ruas and Peters, 1998). Although some of these changes are
silent, some result in the expression of a protein which has lost
its ability to inhibit cdk4 and cdk6. Although such point muta-
tions are extremely rare in lymphoid malignancies (Ruas and
Peters, 1998), we have not eliminated the possibility that they
may be present in some of these B-cell lines.
iv. In addition, the molecular mechanisms by which p16INK4a
expression can be altered includes silencing of the locus by
site-specific methylation (Herman et al, 1995; Merlo et al,
1995; Otterson et al, 1995; Shapiro et al, 1995a,b). However,
since we were able to detect expression of p16INK4a protein in
these B-cell lines, this silencing mechanism is unlikely to play
a significant role here.
The possibility remains that the p16INK4a/pRb pathway is
disrupted further downstream or bypassed in these cells. For
example, it has been shown recently that elevated expression of
either cyclin E or c-myc is able to promote G1 to S phase transition
in the presence of hypophosphorylated, active pRb (Alevizopoulos
et al, 1997; Leone et al, 1997; Lukas et al, 1997). Since all
Burkitt’s lymphoma cells express elevated levels of c-myc due to a
translocation involving c-myc and one of the immunoglobulin loci
(Rickinson and Keiff, 1996), this may reduce the selective pres-
sure for mutations in the p16INK4a/pRb pathway during the develop-
ment of the tumour.
Thus, this panel of 11 cell lines, derived originally from B-cell
malignancies (Burkitt’s lymphomas) or Epstein–Barr virus trans-
formation (lymphoblastoid cell lines) appear to express functional
pRb and contain an active pRb phosphorylation pathway. In addi-
tion, this analysis demonstrates that the MTS1 locus is not silenced
in the cell lines. From this, it can be concluded that neither theBritish Journal of Cancer (1999) 80(5/6), 670–675
674 AJ Sinclair and V Frostdisruption of pRb function nor the silencing of MTS1 are
absolutely required either for the generation of B-cell malignan-
cies or for the subsequent outgrowth of B-cell lines.
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